

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use

Sixth Amendment and Response to Office Action

Filed: February 10, 2000

Page 2

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier ; and a protein consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment lacks one or more carbohydrate moieties linked to naturally glycosylated forms of the fragment, and wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the deglycosylated kringle 1-3 region fragment and a glycosylated form of the fragment are at a ratio of 100:0.
2. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.
3. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.
4. (Currently Amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at an amino acid position corresponding to ~~the~~ an N-glycosylation site of human plasminogen.
5. (Cancelled)
6. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.
7. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use
Sixth Amendment and Response to Office Action

Filed: February 10, 2000

Page 3

8. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

9. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

10-12. (Cancelled)

13-14 (Cancelled)

15. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

16. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

17-26 (Cancelled)

27. (Previously Presented) A deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

28. (Cancelled)

29. (Currently Amended) The composition of claim 1 40, further ~~comprising a protein consisting of a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein,~~ wherein the amount of the naturally glycosylated kringle 1-3 region fragment present in the composition is smaller than the amount of the deglycosylated kringle 1-3 region fragment present in the composition.

30-34. (Cancelled)

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use

Sixth Amendment and Response to Office Action

Filed: February 10, 2000

Page 4

35. (Currently Amended) The composition of claim 29 39, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

36. (Cancelled)

37. (Currently Amended) The composition of claim 29 39, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

38. (Currently Amended) The composition of claim 29 39, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

39. (New) A composition comprising a pharmaceutically acceptable carrier and a protein consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein wherein the deglycosylated kringle 1-3 region fragment lacks one or more carbohydrate moieties linked to naturally glycosylated forms of the fragment, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

40. (New) The composition of claim 39, further comprising a protein consisting of a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein.

41. (New) The composition of claim 27, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

42. (New) The composition of claim 27, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

43. (New) The composition of claim 27, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.